Chengyi Pharmaceutical: obtaining drug registration certificate for azathioprine tablets

On the evening of October 31st, Chengyi Pharmaceutical announced that the company had recently received a "Drug Registration Certificate" for azathioprine tablets approved and issued by the National Drug Administration. Azathioprine tablets are suitable for acute and chronic leukemia, severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, autoimmune chronic active hepatitis, nodular polyarteritis, autoimmune hemolytic anemia, and spontaneous thrombocytopenic purpura; The combination of azathioprine tablets with corticosteroids and/or other immunosuppressive agents and treatment measures can prevent rejection reactions in organ transplant (kidney transplant, heart transplant, and liver transplant) patients and reduce the demand for corticosteroids in kidney transplant patients.

(Editor Wang Shijun)

Article source: Securities Daily website